Susquehanna International Group, LLP Syndax Pharmaceuticals Inc Put Options Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$17.93 - $24.81 $3.07 Million - $4.24 Million	171,000 Added 581.63%	200,400 $3.86 Million
Q2 2024 Aug 15, 2024	SELL	$18.82 - $23.79 $1.34 Million - $1.7 Million	-71,300 Reduced 70.8%	29,400 $603,000
Q1 2024 May 07, 2024	SELL	$19.71 - $24.57 $944,109 - $1.18 Million	-47,900 Reduced 32.23%	100,700 $2.4 Million
Q4 2023 Feb 14, 2024	SELL	$11.39 - $21.67 $6.21 Million - $11.8 Million	-545,200 Reduced 78.58%	148,600 $3.21 Million
Q3 2023 Nov 14, 2023	BUY	$14.52 - $21.77 $8.58 Million - $12.9 Million	590,800 Added 573.59%	693,800 $10.1 Million
Q2 2023 Aug 11, 2023	BUY	$19.35 - $22.31 $1.99 Million - $2.3 Million	103,000 New	103,000 $2.16 Million
Q4 2022 Feb 14, 2023	BUY	$20.64 - $26.24 $1.13 Million - $1.44 Million	54,800 Added 299.45%	73,100 $1.86 Million
Q3 2022 Nov 14, 2022	SELL	$18.51 - $24.79 $27,765 - $37,185	-1,500 Reduced 7.58%	18,300 $440,000

227

88.3M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $895M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.